Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process

Journal of the Neurological Sciences

Volumn 276, Issue 1-2, 2009, Pages 38-40

  Harel, Yermi ^a,c   Appleboim, Nava ^b   Lavie, Mor ^b   Achiron, Anat ^b,c  

^a Lewenstein Rehabilitation Hospital   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Impaired attention; Methylphenidate; Multiple sclerosis

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADULT; ARTICLE; ATTENTION DISTURBANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEARING TEST; HUMAN; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; YOUNG ADULT;

EID: 58149148227     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.08.025     Document Type: Article

References (21)

1. Rao S.M., Leo G.J., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41 (1991) 685-691
2. Brassington J.C., and Marh N.V. Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev 8 (1998) 43-77
3. Lyon-Caen O., Jouvent R., Hauser S., Chaunu M.P., Benoit N., Widlocher D., and Lhermitte F. Cognitive functions in recent-onset demyelinating diseases. Arch Neurol 43 (1986) 1138-1141
4. Achiron A., and Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 74 (2003) 443-446
5. Dujardin K., Donze A.C., and Hautecoeur P. Attention impairment in recently diagnosed multiple sclerosis. Eur J Neurol 5 (1998) 61-66
6. Groves P.M., and Tepper J.M. Neuronal mechanisms of action of amphetamine. In: Creese I. (Ed). Stimulants: neurochemical, behavioral, and clinical perspectives (1983), Raven Press, New York 81-129
7. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94 (1998) 127-152
8. de Sonneville L.M.J., Njiokiktjien C., and Bos H. Methylphenidate and information processing. Part I: Differentiation between responders and nonresponders; part 2: efficacy in responders. J Clin Exp Neuropsychol 16 (1994) 877-897
9. Carlson C.L., Pelham W.E., Swanson J.M., and Wagner J.L. A divided attention analysis of the effects of methylphenidate on the arithmetic performance of children with attention deficit hyperactivity disorder. J Child Psychol Psychiatry 32 (1991) 463-471
10. Losier B.J., McGrath P.J., and Klein R.M. Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry 37 (1996) 971-987
11. Whyte J., Vaccaro M., Grieb-Neff P., and Hart T. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. J Head Trauma Rehabil 17 (2002) 284-299
12. Meyers C.A., Weitzner M.A., Valentine A.D., and Levin V.A. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16 (1998) 2522-2527
13. Forn C., Barros-Loscertales A., Escudero J., Belloch V., Campos S., Parcet M.A., et al. Cortical reorganization during PASAT task in MS patients with preserved working memory functions. NeuroImage 31 (2006) 686-691
14. Kalkers N.F., de Groot V., Lazeron R.H., Killestein J., Adèr H.J., Barkhof F., et al. Polman CH. MS functional composite. Relation to disease phenotype and disability strata. Neurology 54 (2000) 1233-1239
15. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
16. Rao S.M. Cognitive function study group of the national multiple sclerosis society. A manual for the brief repeatable battery of neuropsychological test in multiple sclerosis (1990), Medical College of Wisconsin, Milwaukee, WI
17. Pietrzak R.H., Mollica C.M., Maruff P., and Snyder P.J. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 30 (2006) 1225-1245
18. Sangal R.B., and Sangal J.M. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate. Clin Neurophysiol 115 (2004) 188-193
19. Winsberg B.G., Javitt D.C., and Silipo G.S. Electrophysiological indices of information processing in methylphenidate responders. Biol Psychiatry 42 (1997) 434-445
20. Gonzalez-Rosa J.J., Vazquez-Marrufo M., Vaquero E., Duque P., Borges M., Gamero M.A., et al. Differential cognitive impairment for diverse forms of multiple sclerosis. BMC Neurosci 7 (2006) 39
21. Aminoff J.C., and Goodin D.S. Long-latency cerebral event-related potentials in multiple sclerosis. J Clin Neurophysiol 18 (2001) 372-377